SCAG

----

Pre-market hot trades in US stocks: BitMine Immersion Tech up 3.11% in pre-market

LongbridgeAII'm LongbridgeAI, I can summarize articles.

BitMine Immersion Tech pre-market up 3.11%; Scage Future pre-market up 200.00%; Basel Medical pre-market up 60.99%; Calidi Biotherapeutics pre-market up 55.22%

Pre-market Hot Trades in US Stocks

BitMine Immersion Tech is up 3.11% in pre-market trading. Based on recent important news:

  1. On June 30, Bitmine Immersion Technologies announced the completion of a $250 million private placement, planned for its Ethereum financial strategy, with the stock price rising 41.15% in pre-market.

  2. On July 1, the company announced its Ethereum financial strategy, with the stock price soaring 40.5% in pre-market.

  3. On July 4, the stock price surged again by 130.8% due to the market's positive response to the company's Ethereum strategy.

Top Gainers in Pre-market US Stocks

Scage Future is up 200.00% in pre-market trading. Based on recent important news:

  1. On May 21, during JP Morgan's Investor Day event, Jamie Dimon pointed out the complacency in the market, with investors favoring call options, anticipating a market rise.

  2. On May 19, Li Ming, Vice Chairman of the Securities Regulatory Commission, stated that A-share valuations are low, encouraging restructuring to enhance market vitality.

  3. On May 11, the central bank established re-lending for service consumption and elderly care, supporting financial institutions to increase support for key areas.

Basel Medical is up 60.99% in pre-market trading. Based on recent important news:

  1. On June 27, Basel Medical received a lock-up period waiver, paving the way for potential strategic financing, with the stock price soaring 60.99%.

  2. On June 26, Basel Medical announced plans for strategic financing, enhancing market expectations and driving the stock price up.

  3. On May 29, Basel Medical reaffirmed its strong financial position, stabilizing investor confidence.

Calidi Biotherapeutics is up 55.22% in pre-market trading. Based on recent key news:

  1. On July 8, Calidi Biotherapeutics announced its mention in an editorial published by NetworkNewsWire, increasing market attention and leading to a significant rise in stock price.

  2. On July 7, the company launched a new biotherapeutic product, with positive market response driving the stock price further up.

  3. On July 6, industry analysts gave positive evaluations of Calidi's future growth potential, boosting investor confidence

Source: Price Alert The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.